308 related articles for article (PubMed ID: 19276167)
1. Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions.
Gopal YN; Chanchorn E; Van Dyke MW
Mol Cancer Ther; 2009 Mar; 8(3):552-62. PubMed ID: 19276167
[TBL] [Abstract][Full Text] [Related]
2. Combination of a p53-activating CP-31398 and an MDM2 or a FAK inhibitor produces growth suppressive effects in mesothelioma with wild-type p53 genotype.
Zhong B; Shingyoji M; Hanazono M; Nguyễn TT; Morinaga T; Tada Y; Shimada H; Hiroshima K; Tagawa M
Apoptosis; 2020 Aug; 25(7-8):535-547. PubMed ID: 32468177
[TBL] [Abstract][Full Text] [Related]
3. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
4. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
[TBL] [Abstract][Full Text] [Related]
5. The histone demethylase JMJD2B is critical for p53-mediated autophagy and survival in Nutlin-treated cancer cells.
Duan L; Perez RE; Lai X; Chen L; Maki CG
J Biol Chem; 2019 Jun; 294(23):9186-9197. PubMed ID: 31036564
[TBL] [Abstract][Full Text] [Related]
6. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
[TBL] [Abstract][Full Text] [Related]
7. Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer.
Singh AK; Chauhan SS; Singh SK; Verma VV; Singh A; Arya RK; Maheshwari S; Akhtar MS; Sarkar J; Rangnekar VM; Chauhan PMS; Datta D
Carcinogenesis; 2016 Nov; 37(11):1027-1040. PubMed ID: 27543608
[TBL] [Abstract][Full Text] [Related]
8. On p53 revival using system oriented drug dosage design.
Haseeb M; Azam S; Bhatti AI; Azam R; Ullah M; Fazal S
J Theor Biol; 2017 Feb; 415():53-57. PubMed ID: 27979498
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
[TBL] [Abstract][Full Text] [Related]
10. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
[TBL] [Abstract][Full Text] [Related]
11. FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2.
Liu T; Xiong J; Yi S; Zhang H; Zhou S; Gu L; Zhou M
Oncogene; 2017 Mar; 36(12):1678-1686. PubMed ID: 27617579
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay.
Herman AG; Hayano M; Poyurovsky MV; Shimada K; Skouta R; Prives C; Stockwell BR
Cancer Discov; 2011 Sep; 1(4):312-25. PubMed ID: 22586610
[TBL] [Abstract][Full Text] [Related]
13. Development of selective small molecule MDM2 degraders based on nutlin.
Wang B; Wu S; Liu J; Yang K; Xie H; Tang W
Eur J Med Chem; 2019 Aug; 176():476-491. PubMed ID: 31128449
[TBL] [Abstract][Full Text] [Related]
14. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.
Zhang L; Zhang J; Hu C; Cao J; Zhou X; Hu Y; He Q; Yang B
Anticancer Drugs; 2009 Jul; 20(6):416-24. PubMed ID: 19579266
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
[TBL] [Abstract][Full Text] [Related]
16. The hydrophobically-tagged MDM2-p53 interaction inhibitor Nutlin-3a-HT is more potent against tumor cells than Nutlin-3a.
Nietzold F; Rubner S; Berg T
Chem Commun (Camb); 2019 Nov; 55(95):14351-14354. PubMed ID: 31720601
[TBL] [Abstract][Full Text] [Related]
17. TRIAD1 inhibits MDM2-mediated p53 ubiquitination and degradation.
Bae S; Jung JH; Kim K; An IS; Kim SY; Lee JH; Park IC; Jin YW; Lee SJ; An S
FEBS Lett; 2012 Sep; 586(19):3057-63. PubMed ID: 22819825
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Mdm2 sensitizes human retinal pigment epithelial cells to apoptosis.
Bhattacharya S; Ray RM; Chaum E; Johnson DA; Johnson LR
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3368-80. PubMed ID: 21345989
[TBL] [Abstract][Full Text] [Related]
19. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
Sriraman A; Radovanovic M; Wienken M; Najafova Z; Li Y; Dobbelstein M
Oncotarget; 2016 May; 7(22):31623-38. PubMed ID: 27183917
[TBL] [Abstract][Full Text] [Related]
20. MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells.
Wang B; Fang L; Zhao H; Xiang T; Wang D
Acta Biochim Biophys Sin (Shanghai); 2012 Aug; 44(8):685-91. PubMed ID: 22843172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
